Collectively, these results suggest that targeting PUS1 with Mogroside IV-E may represent a promising therapeutic strategy for metastatic prostate cancer, as it not only inhibits tumor cell migration and invasion but also improves survival outcomes in xenograft mice. Here, PUS1 is linked to neoplasm.